Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot International flag

This page is part of the Evidence Based Medicine on FHIR Implementation Guide (v1.0.0-ballot: STU1 Ballot 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. . For a full list of available versions, see the Directory of published versions

: SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer - Brian S. Alper - TTL Representation

Active as of 2023-11-26

Raw ttl | Download


@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

 a fhir:Library ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "179632"] ; # 
  fhir:meta [
fhir:versionId [ fhir:v "2" ] ;
fhir:lastUpdated [ fhir:v "2023-11-26T22:51:21.545Z"^^xsd:dateTime ] ;
    ( fhir:profile [
fhir:v "http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-excluded-studies"^^xsd:anyURI ;
fhir:link <http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-excluded-studies>     ] )
  ] ; # 
  fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2>Participants</h2><table class=\"grid\"><tr><td>Author</td><td>Brian S. Alper</td></tr></table><h2>Related Artifacts</h2><table class=\"grid\"><tr><td>derived-from</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr><tr><td>contains</td><td/></tr></table><h2>Contents</h2></div>"
  ] ; # 
  fhir:extension ( [
fhir:url [ fhir:v "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg"^^xsd:anyURI ] ;
fhir:value [ fhir:v "cds" ]
  ] ) ; # 
  fhir:url [ fhir:v "https://fevir.net/resources/Library/179632"^^xsd:anyURI] ; # 
  fhir:identifier ( [
fhir:type [
      ( fhir:coding [
fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/v2-0203"^^xsd:anyURI ] ;
fhir:code [ fhir:v "ACSN" ] ;
fhir:display [ fhir:v "Accession ID" ]       ] ) ;
fhir:text [ fhir:v "FEvIR Object Identifier" ]     ] ;
fhir:system [ fhir:v "https://fevir.net"^^xsd:anyURI ] ;
fhir:value [ fhir:v "179632" ] ;
fhir:assigner [
fhir:display [ fhir:v "Computable Publishing LLC" ]     ]
  ] ) ; # 
  fhir:version [ fhir:v "1.0.0-ballot"] ; # 
  fhir:title [ fhir:v "SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer - Brian S. Alper"] ; # 
  fhir:status [ fhir:v "active"] ; # 
  fhir:type [
    ( fhir:coding [
fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/library-type"^^xsd:anyURI ] ;
fhir:code [ fhir:v "asset-collection" ] ;
fhir:display [ fhir:v "Asset Collection" ]     ] )
  ] ; # 
  fhir:subject [
a fhir:Reference ;
fhir:reference [ fhir:v "Group/179619" ] ;
fhir:type [ fhir:v "Group"^^xsd:anyURI ] ;
fhir:display [ fhir:v "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer" ]
  ] ; # 
  fhir:date [ fhir:v "2023-11-26T18:15:27.442Z"^^xsd:dateTime] ; # 
  fhir:publisher [ fhir:v "HL7 International / Clinical Decision Support"] ; # 
  fhir:contact ( [
fhir:name [ fhir:v "HL7 International / Clinical Decision Support" ] ;
    ( fhir:telecom [
fhir:system [ fhir:v "url" ] ;
fhir:value [ fhir:v "http://www.hl7.org/Special/committees/dss" ]     ] )
  ] ) ; # 
  fhir:description [ fhir:v "11 excluded studies"] ; # 
  fhir:useContext ( [
fhir:code [
fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ;
fhir:code [ fhir:v "evidence-communication" ] ;
fhir:display [ fhir:v "Evidence Communication" ]     ] ;
fhir:value [
a fhir:CodeableConcept ;
      ( fhir:coding [
fhir:system [ fhir:v "https://fevir.net/resources/CodeSystem/179423"^^xsd:anyURI ] ;
fhir:code [ fhir:v "SystematicReviewExcludedStudies" ] ;
fhir:display [ fhir:v "SystematicReviewExcludedStudies" ]       ] )     ]
  ] ) ; # 
  fhir:jurisdiction ( [
    ( fhir:coding [
fhir:system [ fhir:v "http://unstats.un.org/unsd/methods/m49/m49.htm"^^xsd:anyURI ] ;
fhir:code [ fhir:v "001" ] ;
fhir:display [ fhir:v "World" ]     ] )
  ] ) ; # 
  fhir:copyright [ fhir:v "https://creativecommons.org/licenses/by-nc-sa/4.0/"] ; # 
  fhir:author ( [
fhir:name [ fhir:v "Brian S. Alper" ]
  ] ) ; # 
  fhir:relatedArtifact ( [
fhir:type [ fhir:v "derived-from" ] ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179613" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis." ]     ]
  ] [
fhir:type [ fhir:v "contains" ] ;
    ( fhir:classifier [
fhir:text [ fhir:v "Different comparison (ADT versus ADT plus estramustine)" ]     ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179628" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist." ]     ]
  ] [
fhir:type [ fhir:v "contains" ] ;
    ( fhir:classifier [
fhir:text [ fhir:v "Different comparison (ADT versus ADT plus chemotherapy without docetaxel)" ]     ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179631" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer." ]     ]
  ] [
fhir:type [ fhir:v "contains" ] ;
    ( fhir:classifier [
fhir:text [ fhir:v "Different comparison (ADT versus ADT plus radiotherapy)" ]     ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179627" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial." ]     ]
  ] [
fhir:type [ fhir:v "contains" ] ;
    ( fhir:classifier [
fhir:text [ fhir:v "Different comparison (ADT versus ADT plus radiotherapy)" ]     ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179626" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial." ]     ]
  ] [
fhir:type [ fhir:v "contains" ] ;
    ( fhir:classifier [
fhir:text [ fhir:v "Different comparison (ADT versus ADT plus radiotherapy)" ]     ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179625" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial." ]     ]
  ] [
fhir:type [ fhir:v "contains" ] ;
    ( fhir:classifier [
fhir:text [ fhir:v "Nonrandomized" ]     ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179629" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer." ]     ]
  ] [
fhir:type [ fhir:v "contains" ] ;
    ( fhir:classifier [
fhir:text [ fhir:v "Neoadjuvant treatment" ]     ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179624" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer." ]     ]
  ] [
fhir:type [ fhir:v "contains" ] ;
    ( fhir:classifier [
fhir:text [ fhir:v "Nonrandomized" ]     ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179622" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra." ]     ]
  ] [
fhir:type [ fhir:v "contains" ] ;
    ( fhir:classifier [
fhir:text [ fhir:v "High-risk localized prostate cancer" ]     ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179621" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial." ]     ]
  ] [
fhir:type [ fhir:v "contains" ] ;
    ( fhir:classifier [
fhir:text [ fhir:v "Locally advanced or metastatic (without metastatic subgroup analysis)" ]     ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179630" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer." ]     ]
  ] [
fhir:type [ fhir:v "contains" ] ;
    ( fhir:classifier [
fhir:text [ fhir:v "Nonrandomized" ]     ] ) ;
fhir:resourceReference [
fhir:reference [ fhir:v "Citation/179623" ] ;
fhir:type [ fhir:v "Citation"^^xsd:anyURI ] ;
fhir:display [ fhir:v "23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer." ]     ]
  ] ) . #